ProCE Banner Series

APPlexus Oncology Mid-Year Review: Breast Cancer

APPlexus Mid-Year is a live webinar designed to address educational needs specific to advanced practice providers who care for patients with breast cancer. This webinar will navigate expert insights and recent clinical updates and deliver innovative, real-time education to nurse practitioners and physician associates worldwide. Our mission is to bridge knowledge gaps, untangle controversies, and spotlight pivotal data in a digestible and engaging format.

  AAPA
  | ACPE
  | AMA
  | ANCC
Who Should Attend

This educational program is intended for physicians, nurse practitioners, nurses, pharmacists, physician associates, and other healthcare professionals who care for patients with breast cancer.

All Events

APPlexus Oncology Mid-Year Review: Breast Cancer 

Upcoming Events

August

03

2024

11:00 AM - 2:10 PM Eastern Time (ET)

Virtual

Faculty

ProCE Banner Faculty
Ruta D Rao, MD

Professor of Medicine
Medical Director, Rush University Cancer Center
Rush University Medical Center
Chicago, Illinois

ProCE Banner Faculty
Laura M. Spring, MD

Breast Medical Oncologist
Mass General Cancer Center
Harvard Medical School
Boston, Massachusetts

Topics

Breast Cancers

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Improving Outcomes in Patients With High-Risk Breast Cancer: Expert Guidance and Team Training for HR-Positive/HER2-Negative Disease

Goal Statement
The goal of this program is to inform and build the necessary skills of target learners to optimize their care of patients with high-risk HR-positive HER2-negative breast cancer.

Target Audience
This program is intended for medical oncologists, pharmacists, nurse practitioners, physician associates, nurses, and other healthcare professionals who care for patients with breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

    • Assess risk in patients with HR+/HER2- EBC and MBC to guide optimal therapy selection for patients with high-risk features in order to improve clinical outcomes
    • Select individualized adjuvant therapies for patients with high-risk, HR+/HER2- EBC based on tumor characteristics, predictive biomarkers, the latest clinical data, approvals, guidelines, and expert recommendations
    • Plan an individualized sequence of therapies for patients with high-risk, HR+/HER2- MBC based on risk assessment, the latest clinical data, approvals, guidelines, and expert recommendations
    • Implement evidence-based management of adverse events associated with CDK4/6 inhibitors for high-risk HR+/HER2- breast cancer
    • Promote adherence to oral targeted therapies in patients with HR+/HER2- breast cancer

Sequencing Treatment in HER2-Positive Metastatic Breast Cancer

Goal Statement
The goal of this program is to improve the knowledge, competence, and performance of learners in the optimal use of HER2-targeted agents for patients with breast cancer.

Target Audience
This educational program is intended physicians, nurses, pharmacists, physician associates, and other healthcare professionals who care for patients with HER2-positive metastatic breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

    • Sequence HER2-directed therapies for breast cancer treatment in accordance with consensus recommendations
    • Gain a deeper understanding of the role of HER2 in breast cancer and the rationale for targeting HER2 with newer agents
    • Manage adverse events assocated with newer agents used to treat HER2-positive breast cancer

Accreditation

Improving Outcomes in Patients With High-Risk Breast Cancer: Expert Guidance and Team Training for HR-Positive/HER2-Negative Disease
Sequencing Treatment in HER2-Positive Metastatic Breast Cancer

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Improving Outcomes in Patients With High-Risk Breast Cancer: Expert Guidance and Team Training for HR-Positive/HER2-Negative Disease: 1.0
  • Sequencing Treatment in HER2-Positive Metastatic Breast Cancer: 1.0

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 2.0 contact hours.

  • Improving Outcomes in Patients With High-Risk Breast Cancer: Expert Guidance and Team Training for HR-Positive/HER2-Negative Disease: 1.0
  • Sequencing Treatment in HER2-Positive Metastatic Breast Cancer: 1.0

Continuing Pharmacy Education

CCO designates this continuing education activity for 2.0 contact hours (0.20 CEUs) of the Accreditation Council for Pharmacy Education.

  • Improving Outcomes in Patients With High-Risk Breast Cancer: Expert Guidance and Team Training for HR-Positive/HER2-Negative Disease -
    JA4008176-0000-24-045-L01-P
  • Sequencing Treatment in HER2-Positive Metastatic Breast Cancer - JA4008176-0000-24-055-L01-P

Universal Activity Number: specific to topic

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. PAs should only claim commensurate with the extent of their participation.

  • Improving Outcomes in Patients With High-Risk Breast Cancer: Expert Guidance and Team Training for HR-Positive/HER2-Negative Disease: 1.0
  • Sequencing Treatment in HER2-Positive Metastatic Breast Cancer: 1.0

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Improving Outcomes in Patients With High-Risk Breast Cancer: Expert Guidance and Team Training for HR-Positive/HER2-Negative Disease

Provided by Clinical Care Options, LLC

Supported by an educational grant from Lilly.

Sequencing Treatment in HER2-Positive Metastatic Breast Cancer 

Provided by Clinical Care Options, LLC

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.